Does treatment of nonsleepy OSA with CPAP therapy change CVD risk? A systematic review.

Sleep MedJun 23, 2026 (epub)
Clinical ResearchCardiologyPulmonology

Kiran Abraham-Aggarwal, Christie Hung, Xiaoxuan Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of CPAP therapy on cardiovascular outcomes in adults with nonsleepy obstructive sleep apnea (OSA). The analysis included 12 studies, primarily randomized controlled trials. The key finding was a significant reduction in diastolic blood pressure (DBP) of -2.33 mmHg, while systolic blood pressure (SBP) showed no significant change.

Key findings

  • CPAP therapy resulted in a significant reduction in diastolic blood pressure of -2.33 mmHg.
  • Systolic blood pressure showed no significant reduction with a pooled estimate of -0.42 mmHg.
  • Cardiovascular event outcomes were inconsistent across the studies reviewed.
  • Adherence to CPAP therapy influenced the observed blood pressure reductions.

Why it matters

Understanding the cardiovascular effects of CPAP in nonsleepy OSA is crucial, as these patients may not exhibit typical symptoms but still face elevated cardiovascular risks. This evidence can inform treatment decisions and patient management strategies.

Source

PubMed · PMID 42349065

Published in Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.